Supplement: Tables and Figures
|
|
- Melvyn Shaw
- 5 years ago
- Views:
Transcription
1 Supplement: Tables and Figures Supplement Table 1. Baseline Characteristics by Study and Efavirenz Assignment Supplement Table 2. Baseline Psychoactive Medications by Efavirenz Assignment* Supplement Table 3. Suicidality Events by Country Supplement Table 4. Restricted to the United States: Suicidality Events by Study Supplement Table 5. Association Between Baseline Characteristics and Hazard of Suicidality (ITT Approach)* Supplement Table 6. Restricted to the United States: Association Between Baseline Characteristics and Hazard of Suicidality (ITT DSMB) Supplement Table 7. Restricted to the United States: Association Between Baseline Characteristics and Hazard of Suicidality (ITT Approach) Supplement Table 8. Cause of Death Classifications (ITT) Supplement Figure 1. Association between efavirenz and hazard of suicidality, according to baseline characteristics (ITT DSMB primary approach). Supplement Figure 2. Association between efavirenz and hazard of suicidality, according to baseline characteristics (ITT sensitivity approach).
2 Supplement Table 1. Baseline Characteristics by Study and Efavirenz Assignment Characteristic A5095 (N=765) A5095 -free (N=382) A5142 (N=502) A5142 -free (N=255) A5175 (N=1045) A5175 -free (N=526) A5202 (N=929) Country Brazil (15%) 76 (14%) Haiti (7%) 32 (6%) India (16%) 86 (16%) Malawi (14%) 74 (14%) Peru (8%) 48 (9%) South Africa (2%) 8 (3%) 140 (13%) 70 (13%) A5202 -free (N=928) Thailand (6%) 33 (6%) United States 765 (100%) 382 (100%) 490 (98%) 247 (97%) 140 (13%) 70 (13%) 929 (100%) 928 (100%) Zimbabwe (7%) 37 (7%) Sex Male 620 (81%) 309 (81%) 410 (82%) 195 (76%) 562 (54%) 270 (51%) 760 (82%) 775 (84%) Female 145 (19%) 73 (19%) 92 (18%) 60 (24%) 483 (46%) 256 (49%) 169 (18%) 153 (16%) Race or ethnic group (United States) N White Non-Hispanic 313 (41%) 149 (39%) 187 (38%) 88 (36%) 39 (28%) 23 (33%) 371 (40%) 375 (40%) Black Non-Hispanic 271 (35%) 142 (37%) 186 (38%) 109 (44%) 59 (42%) 26 (37%) 315 (34%) 300 (32%) Hispanic 165 (22%) 83 (22%) 103 (21%) 45 (18%) 38 (27%) 18 (26%) 210 (23%) 219 (24%) Asian 10 (1%) 5 (1%) 11 (2%) 4 (2%) 1 (1%) 0 (0%) 13 (1%) 19 (2%) American Indian/Alaska Native 3 (0%) 3 (1%) 2 (0%) 0 (0%) 0 (0%) 2 (3%) 9 (1%) 5 (1%) Other 3 (0%) 0 (0%) 1 (0%) 1 (0%) 3 (2%) 1 (1%) 11 (1%) 10 (1%) Race or ethnic group (Multinational non-us) N White Non-Hispanic (0%) 0 (0%) 55 (6%) 22 (5%) Black Non-Hispanic (100%) 8 (100%) 442 (49%) 219 (48%) Hispanic (0%) 0 (0%) 170 (19%) 96 (21%) Asian (0%) 0 (0%) 238 (26%) 119 (26%) -- --
3 Characteristic A5095 (N=765) A5095 -free (N=382) A5142 (N=502) A5142 -free (N=255) A5175 (N=1045) A5175 -free (N=526) A5202 (N=929) A5202 -free (N=928) Age, years Median (Q1, Q3) 37 (31, 43) 37 (32, 43) 38 (32, 44) 37 (32, 44) 34 (29, 41) 34 (29, 41) 38 (31, 45) 38 (31, 45) < (20%) 61 (16%) 94 (19%) 42 (16%) 287 (27%) 146 (28%) 201 (22%) 203 (22%) (60%) 243 (64%) 285 (57%) 156 (61%) 607 (58%) 310 (59%) 483 (52%) 474 (51%) (20%) 78 (20%) 123 (25%) 57 (22%) 151 (14%) 70 (13%) 245 (26%) 251 (27%) Pre-treatment CD4 count, Median (Q1, Q3) x 10 9 cells/l (0.077, 0.333) (0.079, 0.344) (0.043, 0.315) (0.070, 0.300) (0.089, 0.228) (0.096, 0.235) (0.103, 0.333) (0.081, 0.335) (20%) 65 (17%) 134 (27%) 49 (19%) 137 (13%) 63 (12%) 163 (18%) 176 (19%) (27%) 126 (33%) 125 (25%) 89 (35%) 519 (50%) 238 (45%) 228 (25%) 233 (25%) (30%) 103 (27%) 138 (28%) 81 (32%) 389 (37%) 225 (43%) 341 (37%) 315 (34%) > (23%) 87 (23%) 103 (21%) 36 (14%) 0 (0%) 0 (0%) 196 (21%) 204 (22%) HIV-1 RNA, log 10 copies/ml Median (Q1, Q3) 4.77 (4.38, 5.41) 4.76 (4.40, 5.28) 4.81 (4.42, 5.25) 4.76 (4.47, 5.20) 5.02 (4.59, 5.44) 5.06 (4.55, 5.49) 4.67 (4.34, 4.95) 4.65 (4.31, 5.12) < 100, (61%) 231 (60%) 314 (63%) 163 (64%) 509 (49%) 245 (47%) 714 (77%) 667 (72%) 100, (39%) 151 (40%) 188 (37%) 91 (36%) 536 (51%) 280 (53%) 215 (23%) 261 (28%) History of AIDS None recorded 627 (82%) 303 (79%) 413 (82%) 209 (82%) 932 (89%) 472 (90%) 775 (83%) 778 (84%) Yes 138 (18%) 79 (21%) 89 (18%) 46 (18%) 113 (11%) 54 (10%) 154 (17%) 150 (16%) Injection drug history None recorded 683 (89%) 341 (89%) 454 (90%) 227 (89%) 1,014 (97%) 516 (98%) 840 (90%) 857 (92%) Yes 82 (11%) 41 (11%) 48 (10%) 28 (11%) 31 (3%) 10 (2%) 89 (10%) 71 (8%) Psychiatric history or psychoactive medication* None recorded 521 (68%) 255 (67%) 339 (68%) 176 (69%) 880 (84%) 432 (82%) 492 (53%) 529 (57%) Yes 244 (32%) 127 (33%) 163 (32%) 79 (31%) 165 (16%) 94 (18%) 437 (47%) 399 (43%) Psychoactive medication* None recorded 640 (84%) 320 (84%) 472 (94%) 247 (97%) 996 (95%) 495 (94%) 711 (77%) 744 (80%) Yes 125 (16%) 62 (16%) 30 (6%) 8 (3%) 49 (5%) 31 (6%) 218 (23%) 184 (20%) Depression-related history or antidepressant medication* None recorded 618 (81%) 297 (78%) 405 (81%) 214 (84%) 958 (92%) 472 (90%) 638 (69%) 653 (70%) Yes 147 (19%) 85 (22%) 97 (19%) 41 (16%) 87 (8%) 54 (10%) 291 (31%) 275 (30%)
4 Characteristic Antidepressant medication* A5095 (N=765) A5095 -free (N=382) A5142 (N=502) A5142 -free (N=255) A5175 (N=1045) A5175 -free (N=526) A5202 (N=929) A5202 -free (N=928) None recorded 670 (88%) 335 (88%) 476 (95%) 250 (98%) 1,006 (96%) 505 (96%) 764 (82%) 783 (84%) Yes 95 (12%) 47 (12%) 26 (5%) 5 (2%) 39 (4%) 21 (4%) 165 (18%) 145 (16%) Body mass index, kg/m 2 Median (Q1, Q3) (21.8, 27.6) (21.9, 27.5) (22.0, 27.8) (21.9, 28.1) (20.2, 25.2) (20.1, 24.8) (22.2, 27.9) (22.1, 28.1) Underweight (< 18.5) 29 (4%) 16 (4%) 21 (4%) 9 (4%) 91 (9%) 61 (12%) 37 (4%) 33 (4%) Normal (<25) 377 (52%) 181 (48%) 241 (49%) 127 (51%) 680 (65%) 343 (65%) 438 (47%) 448 (48%) Overweight (<30) 221 (30%) 131 (35%) 155 (31%) 72 (29%) 201 (19%) 87 (17%) 317 (34%) 301 (32%) Obese (30+) 104 (14%) 47 (13%) 79 (16%) 43 (17%) 73 (7%) 35 (7%) 136 (15%) 146 (16%) Baseline weight, kg Median (Q1, Q3) 74 (65, 84) 75 (65, 84) 74 (64, 86) 73 (65, 83) 61 (54, 70) 60 (53, 69) 75 (66, 86) 75 (66, 86) < (15%) 56 (15%) 85 (17%) 37 (15%) 490 (47%) 264 (50%) 123 (13%) 100 (11%) 60-< (51%) 191 (50%) 240 (48%) 135 (53%) 443 (42%) 208 (40%) 469 (50%) 483 (52%) (34%) 132 (35%) 174 (35%) 82 (32%) 112 (11%) 54 (10%) 337 (36%) 345 (37%) =efavirenz. *Prescription psychoactive (or antidepressant) medication ongoing within 30 days before study entry.
5 Supplement Table 2. Baseline Psychoactive Medications by Efavirenz Assignment* Generic name (Trade name) Efavirenz (n=3241) Efavirenz-free (n=2091) Psychoactive Drug Category No. of participants on medication prestudy 422 (13%) 285 (14%) Antidepressant No. of participants on medication prestudy 325 (10%) 217 (10%) Bupropion (Wellbutrin, Zyban) 59 (2%) 42 (2%) Trazodone (Desyrel) 54 (2%) 42 (2%) Sertraline (Zoloft) 46 (1%) 28 (1%) Amitriptyline (Amitrip, Elavil, Endep, Enovil, Trepiline, Tryptanol) 40 (1%) 23 (1%) Citalopram (Celexa) 38 (1%) 23 (1%) Paroxetine (Paxil) 40 (1%) 20 (1%) Escitalopram (Lexapro) 28 (1%) 25 (1%) Fluoxetine (Prozac, Sarafem) 27 (1%) 18 (1%) Venlafaxine (Effexor) 21 (1%) 20 (1%) Mirtazapine (Remeron) 14 (<0.5%) 12 (1%) Doxepin (Adapin, Sinequan) 4 (<0.5%) 7 (<0.5%) Nortriptyline (Aventyl, Pamelor) 6 (<0.5%) 2 (<0.5%) Duloxetine (Cymbalta) 4 (<0.5%) 2 (<0.5%) Imipramine (Janimine, Tofranil) 1 (0%) 2 (<0.5%) Desipramine (Norpramin, Pertofrane) 1 (0%) 0 (0%) Anti-Anxiety No. of participants on medication prestudy 106 (3%) 77 (4%) Alprazolam (Niravam, Xanax) 36 (1%) 30 (1%) Lorazepam (Ativan, Tavor, Temesta) 29 (1%) 24 (1%) Clonazepam (Clonopin, Klonopin, Rivotril) 25 (1%) 13 (1%) Diazepam (Diastat, Valium, Valrelease, Zetran) 12 (<0.5%) 6 (<0.5%) Buspirone (BuSpar) 10 (<0.5%) 4 (<0.5%) Clorazepate Dipotassium (ClorazeCaps, ClorazeTabs, GenENE, Tranxene) 1 (0%) 2 (<0.5%) Chlordiazepoxide (Librium) 0 (0%) 1 (0%) Mood Stabilizing No. of participants on medication prestudy 83 (3%) 42 (2%) Gabapentin (Neurontin) 39 (1%) 24 (1%) Divalproex Sodium (Depakote) 19 (1%) 9 (<0.5%) Lamotrigine (Lamictal) 11 (<0.5%) 7 (<0.5%) Carbamazepine (Atretol, Epitol, Tegretol) 9 (<0.5%) 3 (<0.5%) Oxcarbazepine (Trileptal) 4 (<0.5%) 1 (0%) Lithium Carbonate (Eskalith, Lithane, Lithobid, Lithotabs) 3 (<0.5%) 1 (0%) Topiramate (Topamax) 3 (<0.5%) 0 (0%) Valproate Sodium (Depakene Syrup, DPA sodium) 1 (0%) 0 (0%) Lithium Citrate (Cibalith-S Syrup, Eskalith Lithobid) 1 (0%) 0 (0%) Antipsychotic No. of participants on medication pre-study 42 (1%) 35 (2%) Quetiapine (Seroquel) 14 (<0.5%) 15 (1%) Olanzapine (Zyprexa) 11 (<0.5%) 8 (<0.5%) Risperidone (Risperdal) 8 (<0.5%) 7 (<0.5%) Ziprasidone (Geodon) 4 (<0.5%) 2 (<0.5%) Aripiprazole (Abilify) 1 (0%) 4 (<0.5%)
6 Generic name (Trade name) Efavirenz (n=3241) Efavirenz-free (n=2091) Chlorpromazine (Ormazine, Thorazine) 1 (0%) 1 (0%) Haloperidol (Haldol) 1 (0%) 1 (0%) Amitriptyline & Perphenazine (Etrafon, Triavil) 2 (<0.5%) 0 (0%) Fluphenazine (Permitil, Prolixin) 1 (0%) 1 (0%) Haloperidol Decanoate (Haldol Decanoate) 0 (0%) 1 (0%) Fluphenazine Decanoate (Prolixin Decanoate) 1 (0%) 0 (0%) Trifluoperazine (Stelazine) 1 (0%) 0 (0%) Thioridazine (Mellaril) 0 (0%) 1 (0%) Attention deficit hyperactivity disorder (ADHD) No. of participants on medication prestudy 7 (<0.5%) 10 (1%) Methylphenidate (Concerta, Metadate (CD/ER), Methylin, Ritalin (SR/LA)) 4 (<0.5%) 5 (<0.5%) Amphetamine Salts (Adderall (XR)) 1 (0%) 4 (<0.5%) Atomoxetine (Strattera) 2 (<0.5%) 1 (0%) Antipsychotic & Antidepressant No. of participants on medication prestudy 0 (0%) 1 (0%) Amitriptyline & Chlordiazepoxide (Limbitrol (DS)) 0 (0%) 1 (0%) * Prescription medication ongoing within 30 days before study entry; prescribing indication was not collected
7 Supplement Table 3. Suicidality Events by Country A. Intention-to-Treat Data Safety Monitoring Board Approach Efavirenz-containing Efavirenz-free Country n Events PYs IR (95% CI)* n Events PYs IR (95% CI)* Total n United States (6.38, 12.27) (2.06, 6.63) 3951 India (0.93, 27.62) (0.00, 27.98) 255 Brazil (0.00, 16.42) (0.23, 51.29) 231 South Africa (0.10, 21.55) (0.00, 27.45) 230 Malawi (0.00, 14.71) (0.00, 29.52) 221 Peru (0.18, 39.00) (0.33, 72.82) 134 Zimbabwe (0.00, 28.92) (0.00, 56.12) 110 Haiti (0.00, 35.19) (0.00, 71.50) 100 Thailand (10.84, ) (0.00, 71.88) 100 B. Intention-to-Treat Approach Efavirenz-containing Efavirenz-free Country n Events PYs IR (95% CI)* n Events PYs IR (95% CI)* Total n United States (6.17, 11.09) (2.08, 6.12) 3951 India (2.86, 20.54) (0.84, 25.19) 255 Brazil (0.05, 10.86) (0.10, 22.12) 231 South Africa (0.05, 11.06) (0.10, 21.75) 230 Malawi (0.00, 7.70) (0.00, 15.61) 221 Peru (3.71, 34.89) (0.16, 34.73) 134 Zimbabwe (0.00, 14.30) (0.00, 28.38) 110 Haiti (0.00, 16.52) (0.00, 32.91) 100 Thailand (5.13, 48.20) (0.00, 32.90) 100 IR=incidence rate per 1000 PYs. PYs=person-years. Countries are ordered by sample size. *Exact Poisson 95% confidence interval for crude incidence rate per 1000 PYs
8 Supplement Table 4. Restricted to the United States: Suicidality Events by Study A. Intention-to-Treat Data Safety Monitoring Board Approach Efavirenz-containing Efavirenz-free Study n Events PYs IR (95% CI)* n Events PYs IR (95% CI)* A (2.98, 17.68) (0.07, 15.30) A (3.52, 16.06) (0.49, 14.56) A (5.22, 37.52) (0.00, 23.39) A (5.28, 13.34) (2.05, 7.87) B. Intention-to-Treat Approach Efavirenz-containing Efavirenz-free Study n Events PYs IR (95% CI)* n Events PYs IR (95% CI)* A (3.86, 11.84) (0.25, 7.45) A (3.52, 16.06) (0.49, 14.56) A (4.82, 28.62) (0.11, 23.33) A (5.28, 13.34) (2.05, 7.87) IR=incidence rate per 1000 PYs. PYs=person-years. *Exact Poisson 95% confidence interval for crude incidence rate per 1000 PYs
9 Supplement Table 5. Association Between Baseline Characteristics and Hazard of Suicidality (ITT Approach)* Univariate Models Characteristic DF n HR (95% CI) Randomly assigned treatment group Multivariable model (n=5318, 83 events) P- value HR (95% CI) P-value Efavirenz-containing vs. Efavirenz-free (1.26, 3.49) (1.17, 3.23) Sex Female vs. Male (0.51, 1.43) (0.46, 1.37) 0.41 Race or ethnic group, United States only White vs. Black (0.91, 2.81) Hispanic vs. Black 0.74 (0.33, 1.63) Age categories <30 vs. 45 years (1.44, 6.08) (1.71, 7.48) vs. 45 years 1.64 (0.82, 3.27) 1.81 (0.90, 3.63) CD4 count categories vs. >0.349 x10 9 cells/l (0.19, 0.98) (0.18, 1.09) vs. >0.349 x10 9 cells/l 0.47 (0.24, 0.94) 0.55 (0.27, 1.15) vs. >0.349 x10 9 cells/l 0.87 (0.47, 1.60) 0.90 (0.49, 1.67) HIV-1 RNA categories 100,000 vs. <100,000 copies/ml (0.45, 1.17) (0.51, 1.42) 0.53 History of AIDS Yes vs. No (0.50, 1.72) (0.68, 2.62) 0.40 Injection drug history Yes vs. No (1.82, 5.72) < (1.50, 4.88) <0.001 Psychiatric history or psychoactive Rx Yes vs. No (2.35, 5.88) < (2.33, 6.03) <0.001 BMI categories Underweight (< 18.5) vs. Normal (<25) (0.62, 3.05) Overweight (<30) vs. Normal (<25) 0.68 (0.39, 1.17) Obese (30+) vs. Normal (<25) 0.68 (0.32, 1.43) Weight categories <60 vs. 80 kg (0.67, 2.29) (0.77, 2.86) <80 vs. 80 kg 0.85 (0.50, 1.44) 0.84 (0.49, 1.44) BMI=body mass index. DF=degrees of freedom. HR=hazard ratio. ITT=intention-to-treat. *All on-study follow-up was included (ITT approach); Cox model Wald CI and p-values are presented, each model was stratified by study. In multivariable analysis, race or ethnic group was omitted because analysis of this covariate was restricted to the United States, and BMI category was omitted due to collinearity with body weight and missing height observations; otherwise covariates were included in this multivariable model.
10 Supplement Table 6. Restricted to the United States: Association Between Baseline Characteristics and Hazard of Suicidality (ITT DSMB)* Univariate Models Multivariable model (n=3821, 51 events) Characteristic DF n HR (95% CI) P-value HR (95% CI) Randomly assigned treatment group P- value Efavirenz-containing vs. Efavirenz-free (1.23, 4.38) (1.06, 3.82) Sex Female vs. Male (0.32, 1.57) (0.26, 1.43) 0.26 Race or ethnic group White vs. Black (0.89, 3.12) (0.63, 2.41) 0.47 Hispanic vs. Black 0.81 (0.34, 1.92) 0.75 (0.31, 1.79) Age categories <30 vs. 45 years (0.76, 4.16) (0.88, 5.08) vs. 45 years 1.54 (0.73, 3.25) 1.66 (0.78, 3.54) CD4 count categories vs. >0.349 x10 9 cells/l (0.12, 0.95) (0.08, 0.87) vs. >0.349 x10 9 cells/l 0.54 (0.24, 1.21) 0.49 (0.20, 1.18) vs. >0.349 x10 9 cells/l 0.88 (0.44, 1.74) 0.85 (0.42, 1.69) HIV-1 RNA categories 100,000 vs. <100,000 copies/ml (0.52, 1.73) (0.50, 1.93) 0.95 History of AIDS Yes vs. No (0.57, 2.25) (0.75, 3.88) 0.20 Injection drug history Yes vs. No (1.44, 5.47) (1.16, 4.59) Psychiatric history or psychoactive Rx Yes vs. No (2.28, 7.82) < (1.85, 6.64) <0.001 BMI categories Underweight (< 18.5) vs. Normal (<25) (0.61, 4.94) Overweight (<30) vs. Normal (<25) 0.64 (0.33, 1.22) Obese (30+) vs. Normal (<25) 0.53 (0.21, 1.38) Weight categories <60 vs. 80 kg (0.93, 4.40) (1.14, 6.41) <80 vs. 80 kg 1.23 (0.65, 2.33) 1.28 (0.67, 2.45) BMI=body mass index. DF=degrees of freedom. DSMB=data safety monitoring board. HR=hazard ratio. ITT=intention-to-treat. *Cox model Wald CI and p-values are presented, each model was stratified by study. Multivariable analysis was restricted to participants of white, black, or Hispanic race or ethnic group with complete covariate information; BMI was omitted due to collinearity with body weight and missing height observations.
11 Supplement Table 7. Restricted to the United States: Association Between Baseline Characteristics and Hazard of Suicidality (ITT Approach)* Univariate Models Multivariable model (n=3821, 62 events) Characteristic DF n HR (95% CI) P-value HR (95% CI) P-value Randomly assigned treatment group Efavirenz-containing vs. Efavirenzfree (1.29, 4.16) (1.14, 3.71) Sex Female vs. Male (0.37, 1.51) (0.34, 1.55) 0.41 Race or ethnic group White vs. Black (0.91, 2.81) (0.69, 2.27) 0.35 Hispanic vs. Black 0.74 (0.33, 1.63) 0.72 (0.32, 1.62) Age categories <30 vs. 45 years (1.04, 5.23) (1.31, 6.91) vs. 45 years 1.83 (0.88, 3.79) 2.00 (0.95, 4.18) CD4 count categories vs. >0.349 x10 9 cells/l (0.19, 1.05) (0.20, 1.39) vs. >0.349 x10 9 cells/l 0.51 (0.25, 1.07) 0.58 (0.26, 1.27) vs. >0.349 x10 9 cells/l 0.83 (0.44, 1.55) 0.83 (0.44, 1.57) HIV-1 RNA categories 100,000 vs. <100,000 copies/ml (0.45, 1.38) (0.43, 1.49) 0.48 History of AIDS Yes vs. No (0.44, 1.71) (0.54, 2.72) 0.65 Injection drug history Yes vs. No (1.84, 5.89) < (1.53, 5.14) <0.001 Psychiatric history or psychoactive Rx BMI categories Yes vs. No (2.39, 7.19) < (1.96, 6.13) <0.001 Underweight (< 18.5) vs. Normal (<25) Overweight (<30) vs. Normal (<25) 0.64 (0.36, 1.16) Obese (30+) vs. Normal (<25) 0.53 (0.22, 1.26) (0.50, 3.97) Weight categories <60 vs. 80 kg (0.65, 2.79) (0.77, 3.86) <80 vs. 80 kg 0.97 (0.56, 1.68) 0.99 (0.56, 1.73) BMI=body mass index. DF=degrees of freedom. HR=hazard ratio. ITT=intention-to-treat. *Cox model Wald CI and p-values are presented, each model was stratified by study. Multivariable analysis was restricted to participants of white, black, or Hispanic race or ethnic group with complete covariate information; BMI was omitted due to collinearity with body weight and missing height observations.
12 Supplement Table 8. Cause of Death Classifications (ITT) United States * Multinational All Participants (Total) Efavirenz Efavirenz-free Efavirenz Efavirenz-free Efavirenz Efavirenz-free n=2324 n=1627 n=917 n=464 n=3241 n= PY PY PY PY PY PY Cause of Freq Freq Freq Freq Freq Freq death (%) Incidence (%) Incidence (%) Incidence (%) Incidence (%) Incidence (%) Incidence Suicide (0.26) (0.06) (0.22) (0.25) (0.05) 0.18 Substance Abuse (0.13) (0.12) (0.09) (0.10) 0.36 Homicide (0.22) (0.06) Accident (0.22) (0.18) (0.22) (0.22) (0.14) 0.53 Unknown (0.13) (0.06) (0.55) (0.25) (0.05) 0.18 Other cause (1.29) (1.29) (2.84) (3.23) (1.73) (1.72) 6.42 All causes, (2.02) (1.72) (4.03) (3.23) (2.59) (2.06) total 7.67 ITT= intention-to-treat. PY=person-years. Incidence is presented per 1000 PY. Death frequency and incidence are summarized using the intentionto-treat approach to account for all deaths reported during study follow-up. *United States: Suicide method: gunshot (n=3), hanging (1), overdose (n=2: 1 efavirenz, 1 efavirenz-free), method not reported (1). Substance abuse: substance not reported (2), cocaine (1), heroin (1), amphetamine (1). Accident type: motor vehicle (n=6: 4 efavirenz, 2 efavirenz-free), asphyxia (1 efavirenz-free), fire (1 efavirenz). Multinational (n): Brazil (231), Haiti (100), India (255), Malawi (221), Peru (134), South Africa (230), Thailand (100), Zimbabwe (110). Suicide method: hanging (1), method not reported (1). Homicide: assassinated by gunshot (1), stabbed during a street quarrel (1). Accident type: motor vehicle (1), earthquake (1). Other cause: e.g., infection, cancer, organ failure.
13 Supplement Figure 1. Association between efavirenz and hazard of suicidality, according to baseline characteristics (ITT DSMB primary approach). DSMB=data safety monitoring board. IR=crude incidence rate. ITT=intention-to-treat. PY=person-years. Rx=medication. Univariate estimated hazard ratios were quantified from a Cox model with a Wald CI and p-value, stratified by study, and are plotted on a logarithm scale. The continuous age variable presents the efavirenz association when age is held fixed at 25, 35, and 45 years old. *The first p-value tests the main effect of efavirenz; subsequent p-values test for an interaction between efavirenz and the baseline characteristic. Race or ethnic group was limited to white, black and Hispanic participants enrolled in the United States.
14 Supplement Figure 2. Association between efavirenz and hazard of suicidality, according to baseline characteristics (ITT sensitivity approach). IR=crude incidence rate. ITT=intention-to-treat. PY=person-years. Rx=medication. Univariate estimated hazard ratios were quantified from a Cox model with a Wald CI and p-value, stratified by study, and are plotted on a logarithm scale. The continuous age variable presents the efavirenz association when age is held fixed at 25, 35, and 45 years old. *The first p-value tests the main effect of efavirenz; subsequent p-values test for an interaction between efavirenz and the baseline characteristic. Race or ethnic group was limited to white, black and Hispanic participants enrolled in the United States.
Medications and Children Disorders
Mental Health Comprehensive Services Providing Family Stability and Developing Life Coping Skills Medications and Children Disorders Psychiatric medications can be an effective part of the treatment for
More informationIMPORTANT NOTICE. Changes to dispensing of some Behavioral Health Medications for DC Healthcare Alliance members
IMPORTANT NOTICE Changes to dispensing of some Behavioral Health Medications for DC Healthcare Alliance members These changes apply only to members covered under the DC Healthcare Alliance program Alliance
More informationReview of Psychotrophic Medications. (An approved North Carolina Division of Health Services Regulation Continuing Education Course)
Review of Psychotrophic Medications (An approved North Carolina Division of Health Services Regulation Continuing Education Course) Common Psychiatric Disorders *Schizophrenia *Depression *Bipolar Disorder
More informationAppendix: Psychotropic Medication Reference Tables
Appendix: Psychotropic Medication Reference Tables How to Use these Tables These reference tables are designed to provide clinic staff with specific medication related criteria for the Polypharmacy, Cardiometabolic
More informationPSYCHIATRY INTAKE FORM
Please complete all information on this form. PSYCHIATRY INTAKE FORM Name Date Date of Birth Primary Care Physician Current Therapist/Counselor What are the problem(s) for which you are seeking help? 1.
More informationRichard Heidenfelder M.D. Child, Adolescent and Adult Psychiatry 447 9th Ave San Diego, CA
*We are not accepting any New Patients who are currently taking any controlled pain medications *We are *Note: not completion accepting of the any following New Patients paperwork who and Initial are Screening
More informationGuide to Psychiatric Medications for Children and Adolescents
Guide to Psychiatric Medications for Children and Adolescents by Glenn S. Hirsch, M.D. The following guide includes most of the medications used to treat child and adolescent mental disorders. It lists
More informationDealing with a Mental Health Crisis
Dealing with a Mental Health Crisis Information and Resources for First Responders P... PROFESSIONAL WHAT NAMI DOES NAMI Minnesota is a statewide 501(c)(3) grassroots nonprofit organization dedicated to
More informationOverview and Update on Current Psychopharmacological Medications, Including New Medications in Clinical Trials
SPEAKER NOTES Overview and Update on Current Psychopharmacological Medications, Including New Medications in Clinical Trials Summarized by Thomas T. Thomas New psychotropic medications are coming on the
More informationMental Health Intake Form
Current Symptoms Checklist: (check once for any symptoms present, twice for major symptoms) ( ) ( ) Depressed mood ( ) ( ) Racing thoughts ( ) ( ) Excessive worry ( ) ( ) Unable to enjoy activities ( )
More informationStudy Guidelines for Quiz #1
Annex to Section J Page 1 Study Guidelines for Quiz #1 Theory and Principles of Psychopharmacology, Classifications and Neurotransmitters, Anxiolytics/Antianxiety/Minor Tranquilizers, Stimulants, Nursing
More informationJudges Reference Table for the March 2016 Psychotropic Medication Utilization Parameters for Foster Children
Judges Reference Table for the Psychotropic Medication Utilization Parameters for Foster Children Stimulants for treatment of ADHD Preschool (Ages 3-5 years) Child (Ages 6-12 years) Adolescent (Ages 13-17
More informationMental Health Intake Form
38600 Van Dyke Ave., Suite 200 Sterling Heights, MI 48313 Phone: (586) 933-5395 Fax: (586) 935-0159 Mental Health Intake Form Please complete all information on this form and bring it to the first visit.
More informationHappy Daisy Ltd. New Client intake Form. What are the issues for which you are seeking care?
Happy Daisy Ltd. New Client intake Form Name Date Preferred name Pronouns Referred by Date of birth Age Race What are the issues for which you are seeking care? 1. 2. 3. Please check of any of the symptoms
More informationAAA. add dan campbell artwork cats? Report #12 Changes in Medication Use over Time in Adolescents and Adults with Autism Spectrum Disorders
AAA Adolescents & Adults with Autism A Study of Family Caregiving add dan campbell artwork cats? Report #12 Changes in Medication Use over Time in Adolescents and Adults with Autism Spectrum Disorders
More informationUSF Health Psychiatry Clinic. New Patient Questionnaire Adult
USF Health Psychiatry Clinic New Patient Questionnaire Adult Please mail or fax the completed forms to the address/fax number on the bottom of this page. Completed forms must be received five (5) days
More informationSchedule FDA & literature based indications
Psychotropic Medication List Recommended dosages are intended to serve only as a guide for children. Recommended doses are literature based. Clinicians should consult package insert of medications for
More informationNew Patient Questionnaire
4 Embarcadero Center, Suite 1400, San Francisco, CA 94111 (415) 926-7774 phone; (415) 591-7760 office@sanfranciscopsych.com New Patient Questionnaire Thank you for trusting San Francisco Psychiatry with
More informationTRANSCRANIAL MAGNETIC STIMULATION & BRAIN MUSIC THERAPY
TMS - DEPRESSION HISTORY Date: Patient Name: DOB: How did you hear about TMS? What do you know about TMS? Referring Physician? Name of Practice: Name of Inpatient Treatment for Depression: Name of Inpatient
More informationMay 22, DAL: DAL SUBJECT: Hot Weather Advisory. Dear Administrator/Operator:
May 22, 2013 DAL: DAL 13-11 SUBJECT: Hot Weather Advisory Dear Administrator/Operator: The New York State Department of Health would like to remind you of our expectations regarding the protection of Adult
More informationMO Medicaid Foster Care Drugs FY10-FY14
MO Medicaid Foster Care Drugs FY10-FY14 Medicaid (MO HealthNet) Cost of Drugs given to Missouri Foster Care Children by combinations of Age, Gender, Drug Class and Fiscal Year [Raw Data Provided by Missouri
More informationPsychiatric Illness. In the medical arena psychiatry is a fairly recent field A challenging field Numerous diagnosis
Psychiatric Illness In the medical arena psychiatry is a fairly recent field A challenging field Numerous diagnosis 12,000,000 children infants through 18 y/o nation wide 5,000,000 suffer severely Serious
More informationNorthSTAR. Pharmacy Manual
NorthSTAR Pharmacy Manual Revised October, 2008 Table of I. Introduction II. III. IV. Antidepressants New Generation Antipsychotic Medications Mood Stabilizers V. ADHD Medications VI. Anxiolytics and Sedative-Hypnotics
More informationA Brief Overview of Psychiatric Pharmacotherapy. Joel V. Oberstar, M.D. Chief Executive Officer
A Brief Overview of Psychiatric Pharmacotherapy Joel V. Oberstar, M.D. Chief Executive Officer Disclosures Some medications discussed are not approved by the FDA for use in the population discussed/described.
More informationCENPATICO INTEGRATED CARE BEHAVIORAL HEALTH DRUG LIST BY DRUG CLASS
ANTIDEPRESSANTS ALPHA-2 RECEPTOR ANTAGONIST ANTIDEPRESSANTS MIRTAZAPINE ODT TABLETS 15 MG REMERON SOL 90 30 MIRTAZAPINE ODT TABLETS 30 MG REMERON SOL 45 30 MIRTAZAPINE ODT TABLETS 45 MG REMERON SOL 30
More informationMental Health Medications. National Institute of Mental Health. U.S. Department of HealtH and HUman ServiceS National Institutes of Health
Mental Health Medications National Institute of Mental Health U.S. Department of HealtH and HUman ServiceS National Institutes of Health Contents Mental Health Medications...1 What are psychiatric medications?...1
More informationWelcome and thank you for choosing University of Florida Physicians!
DEPARTMENT OF PSYCHIATRY Tuesday, Division of March Child and 14, Adolescent 2017 Psychiatry 8491 NW 39 th Ave. Gainesville, FL 32606 Phone: 352-265-4357 Fax: 352-627-4163 Welcome and thank you for choosing
More informationPOSITIVE YOUTH CONCEPTS Child and Adolescent Therapy 24 Front Street, Suite 302 Exeter, NH
Date: / / NEW CLIENT FORM Client s Name: Address: City State Zip D.O.B.: / / Age: Sex: ================================================================================== Guardian s Name: Custody: Physical
More information#55 PRESCRIBING AND MONITORING PSYCHI RIC MEDICATIONS
- '_ ADMINISTRA TIVE/FISCAUCLINICAL/PHF POLICY AND PROCEDURES COUNTY OF SANTA BARBARA ALCOHOL, DRUG AND MENTAL HEAL TH SERVICES Section - QUALITY ASSURANCE Effective: 12/1/09 Policy- Director's Approval
More informationNEW PATIENT INTAKE FORM
NEW PATIENT INTAKE FORM Please fill out the following form to the best of your ability. Some sections may not apply to you. We will discuss your responses in greater detail during your first appointment.
More informationALAMEDA COUNTY BEHAVIORAL HEALTH CARE SERVICES MEDICATION FORMULARY
ANTIDEPRESSANTS Serotonin Selective Reuptake Inhibitors citalopram 10, 20, 40 mg, 10 mg/5cc $ 0.40 No escitalopram 10, 20 mg $ 2.60 Yes fluoxetine 10, 20 mg, 20 mg/5 ml $ 0.40 Yes fluvoxamine 25, 50, 100
More informationMedically Accepted Indications for Pediatric Use of Psychotropic Medications by
Key: White Background: Medically Accepted Indication Yellow Backgroun: Medically Accepted Indication Status Not Ascertained Orange Background: Pediatric Indication cited, but not supported Red Background:
More informationCENPATICO INTEGRATED CARE BEHAVIORAL HEALTH DRUG LIST BY DRUG NAME. Use Brand Only
ACAMPROSATE TABLET DELAYED RELEASE ALPHA-TOCOPHEROL CAPSULES ALPRAZOLAM CONCENTRATE 1 MG/ML ALPRAZOLAM ODT TABLET 0.25MG, 0.5MG, 1MG ALPRAZOLAM ODT TABLET 2MG ALPRAZOLAM SR TABLET 24-HOUR ALPRAZOLAM TABLET
More informationAdult Initial Assessment / Patient Questionnaire Page 1
Page 1 Patient Name: Date: Age: Date of Birth: / / Please read the following questions and answer to the best of your ability by placing a checkmark in the appropriate boxes or filling in the blank as
More informationPsychotropic Medications Archana Jhawar, PharmD, BCPP Clinical Faculty of UIC Pharmacy Practice Clinical Psychiatric Pharmacist Jesse Brown VA
Psychotropic Medications Archana Jhawar, PharmD, BCPP Clinical Faculty of UIC Pharmacy Practice Clinical Psychiatric Pharmacist Jesse Brown VA Goals of Medications Use least number at lowest dose to get
More informationU T I L I Z A T I O N E D I T S
I N D I A N A H E A L T H C O V E R A G E P R O G R A M S U T I L I Z A T I O N E D I T S A P R I L 1 9, 2 0 1 2 s for s Refer to Provider Bulletin BT200709 for additional information regarding the Mental
More informationTreat mood, cognition, and behavioral disturbances associated with psychological disorders. Most are not used recreationally or abused
Psychiatric Drugs Psychiatric Drugs Treat mood, cognition, and behavioral disturbances associated with psychological disorders Psychotropic in nature Most are not used recreationally or abused Benzodiazepines
More informationUse Brand Only. Preferred Drug Status PRIOR AUTHORIZATION REQUIRED
Generic Drugs Are Over Brand Drugs Unless Specified As Brand ANTIDEPRESSANTS ALPHA-2 RECEPTOR ANTAGONIST ANTIDEPRESSANTS MIRTAZAPINE REMERON 30 30 MIRTAZAPINE REMERON SOLTAB 30 30 ISOCARBOXAZID TABLETS
More informationHCA BHS Prescribing Guidelines Committee - Approved Medications 2012
Amitriptyline/Perphenazine Triavil MAJOR TRANQUILIZERS Beneficiaries 10/2, 10/4, 25/2, 25/4, 50/4 Aripiprazole Abilify 2mg, 5mg, 10mg, 15mg, 20mg, 30mg Quantity Limit 31 / mo for Asenapine Saphris 5mg,
More informationPSYCHIATRIC DRUGS. Mr. D.Raju, M.pharm, Lecturer
PSYCHIATRIC DRUGS Mr. D.Raju, M.pharm, Lecturer PSYCHIATRIC DRUGS Treat mood, cognition, and behavioral disturbances associated with psychological disorders Psychotropic in nature Most are not used recreationally
More informationThank you for choosing Pine Rest Christian Mental Health Services. We look forward to providing services to you.
Thank you for choosing Pine Rest Christian Mental Health Services. We look forward to providing services to you. In order to make the most of your first appointment, please come at least 30 minutes prior
More informationPsychiatric Distress in Chronic & Terminal Illness Barb Henry, ARNP, MSN
Psychiatric Distress in Chronic & Terminal Illness Barb Henry, ARNP, MSN Psycho-Oncology Consultants, LLC & The University of Cincinnati Central Clinic University of Cincinnati Central Clinic www.centralclinic.org
More informationPatient History Form
Patient History Form Date: / / NAME: Last First Middle Birthdate: / / Age: Sex: F M Please read the following questions and answer to the best of your ability by placing a check mark in the appropriate
More informationSteps for Initiating Electroconvulsive Therapy Treatment
Steps for Initiating Electroconvulsive Therapy Treatment PSYCHIATRISTS CAN REFER PATIENTS FOR ECT TREATMENT AT EL CAMINO HOSPITAL BY CALLING THE ECT NURSE COORDINATOR AT 650-962-5795. Once the referral
More informationAntidepressant Medication Strategies We ve Come a Long Way or Have We? Who Writes Prescriptions for Psychotropic Medications. Biological Psychiatry
Antidepressant Medication Strategies We ve Come a Long Way or Have We? Joe Wegmann, PD, LCSW The PharmaTherapist Joe@ThePharmaTherapist.com 504.587.9798 www.pharmatherapist.com Are you receiving our free
More informationCOMMONLY PRESCRIBED PSYCHOTROPIC MEDICATIONS NAME Generic (Trade) DOSAGE KEY CLINICAL INFORMATION Antidepressant Medications*
COMMONLY PRESCRIBED PSYCHOTROPIC MEDICATIONS NAME Generic (Trade) DOSAGE KEY CLINICAL INFORMATION Antidepressant Medications* Bupropion (Wellbutrin) Start: IR-100 mg bid X 4d then to 100 mg tid; SR-150
More informationLAGUNA BEHAVIORAL Crown Valley Parkway, Suite 140 Phone: (949) Laguna Niguel, CA Fax: (949)
NEW PATIENT INFORMATION - ADULTS CLIENT INFORMATION Patient s Name: Today s Date: Other Names: Date of Birth: Age: Address: Street Apartment City State ZIP E-mail Address: May we contact you via e-mail
More informationMental Illness. Doreen L. Rasp, APN, FNP, PMHNP Advanced Behavioral Counseling
Mental Illness Doreen L. Rasp, APN, FNP, PMHNP Advanced Behavioral Counseling Moodiness Changing Bodies Narcissism Self-Esteem Ignorant Naïve Insecure Self-Centered Independent Adolescence Disorders Affecting
More informationPATIENT FACE SHEET PATIENT NAME: PATIENT DOB: PATIENT PHONE #: INSURANCE: MEMBER ID: GROUP NUMBER: PATIENT ADDRESS
1 P a g e PATIENT FACE SHEET PATIENT NAME: PATIENT DOB: PATIENT PHONE #: INSURANCE: MEMBER ID: GROUP NUMBER: PATIENT ADDRESS PRIOR AUTHORIZATION #: (for office use only) INS. CONTACT NAME/ DIRECT NUMBER:
More informationChild & Adolescent Patient History Questionnaire
Child & Adolescent Patient History Questionnaire Child s Name: Nickname? Date of Birth: you When? Additional Concerns: Past Psychiatric History Has your child ever seen a psychiatrist? If so, please provide
More informationPsychiatric Evaluation Intake Form
Psychiatric Evaluation Intake Form 1. Patient Contact Information Date Patient Name Address Best contact phone number Email address Emergency contact Relationship Phone No Primary Care Physician Tel Fax
More informationNew Patient Information - Adolescent
Scanned Ages 12-17 Dear Parent: To help your clinician understand and help your child, please answer the questions on this form and bring it with you to your child s first appointment. Please print using
More informationmed ed Copyright All rights reserved. No part of this publication can be reproduced without prior written consent of the authors.
med ed Dr. Andrea Murphy, Assistant Professor, School of Nursing, Dalhousie University; Research Associate, Sun Life Financial Chair in Adolescent Mental Health Dr. David Gardner, Associate Professor,
More informationMedications, By Class, in TBI
Medications, By Class, in TBI Generic/Brand Name Drawback Advantage Mood Stabilizers (anti-seizure medications) Carbamazepine (Carbatrol ) (Equetro ) (Tegretol ) Gabapentin (Neurontin ) Lamotrigine (Lamictal
More informationDual Diagnosis: Substance Abuse and Mental Illness
Dual Diagnosis: Substance Abuse and Mental Illness and a review of the major PSYCHIATRIC MEDICINES Mark Stanford, Ph.D. Santa Clara Valley Health & Hospital System Department of Alcohol & Drug Services
More information4/2/13 COMMON CLASSES OF MEDICATIONS. Child & Adolescent Behavioral Medicine & Medication Therapies. Behavioral Medicine & Medication Therapies
Child & Adolescent Behavioral Medicine & Medication Therapies Brian J Cowles, PharmD Associate Professor of Pharmacy Practice Albany College of Pharmacy & Health Sciences; Vermont Campus Behavioral Medicine
More informationDuragesic Patch (fentanyl patch) Prior authorization is not required if prescribed by an oncologist
Pre - PA Allowance Quantity 30 patches every 90 days Prior-Approval Requirements Prior authorization is not required if prescribed by an oncologist Age 2 years of age or older Diagnosis Patient must have
More information1911 Keller Andrews Road Sanford, NC
1911 Keller Andrews Road Sanford, NC 27330 919.777.9355 www.wellcenteredcounseling.com Well CENTERED Today's date: Patient Information: Individual Name: Date of Birth: Age: (first) (last) Gender M/F Ethnicity
More informationPROBE INITIAL ZERO/ DK: Please include any prescription medicines, even if you took them only once.
04/18/01 PHARMACOEPIDEMIOLOGY (PH) *PH1. The next questions are about your use of medicines. First, how many different kinds of prescription medicine have you taken during the past seven days? (IF NEC:
More informationPsychiatric Evaluation Intake Form
Psychiatric Evaluation Intake Form 1. Patient Contact Information Patient Name Preferred Name Last First MI Address Best contact phone number: Email address: Primary Care Physician Tel Fax Pharmacy Phone
More informationAdult Intake Form. Page 1 of 5
Adult Intake Form Current Symptoms Checklist: (check once for any symptoms present, twice for major symptoms) ( ) ( ) Depressed mood ( ) ( ) Racing thoughts ( ) ( ) Excessive worry ( ) ( ) Unable to enjoy
More informationPsychiatric Medications. Positive and negative effects in the classroom
Psychiatric Medications Positive and negative effects in the classroom Teaching the Medicated Child Beverly Bryant, M.D. Hattiesburg Clinic 9/17/14 Introduction According to the National Survey of Children
More informationAHCCCS BEHAVIORAL HEALTH DRUG LIST EFFECTIVE OCTOBER 1, 2016
Generic Drugs Are Preferred Over Brand Name Drugs Unless Specified As Brand Only Federally Reimbursable Drugs Not Listed On The AHCCCS Drug List Are Available Through Prior Authorization Effective Date
More informationMental Health Nursing: Mood Disorders. By Mary B. Knutson, RN, MS, FCP
Mental Health Nursing: Mood Disorders By Mary B. Knutson, RN, MS, FCP A Definition of Mood Prolonged emotional state that influences the person s whole personality and life functioning Adaptive Functions
More informationPSYCHIATRIC HISTORY 6. Are you currently seeing a therapist? (Name & contact phone#)
Cool Springs Psychiatric Group PATIENT HISTORY Patient Name Date of Birth Date form completed: *Please arrive on time and bring this form completed to your appointment to avoid any delay in seeing the
More informationHYSINGLA ER (hydrocodone bitartrate) Prior authorization is not required if prescribed by an oncologist.
Pre - PA Allowance None Prior authorization is not required if prescribed by an oncologist. Prior-Approval Requirements Age 18 years of age or older Diagnosis Patient must have the following: 1. Pain,
More informationProfessor David Castle. Ms. Nga Tran. St. Vincent s Mental Health Level 2, 46 Nicholson Street, Fitzroy Vic 3065
ARABIIC Professor David Castle Ms. Nga Tran St. Vincent s Mental Health Level 2, 46 Nicholson Street, Fitzroy Vic 3065 (03) 9288 4147 (03) 9288 4751 Psychiatric Medication Information / Arabic 1 Psychiatric
More informationMORPHINE IR DRUG CLASS Morphine IR, Dilaudid IR (hydromorphone), Opana IR (oxymorphone)
Pre - PA Allowance Tablets & Suppositories Morphine sulfate tablets Morphine sulfate suppositories Oxymorphone tablets Hydromorphone tablets Hydromorphone suppositories 360 tablets per 90 days OR 360 suppositories
More informationPre - PA Allowance. Prior-Approval Requirements LEVORPHANOL TARTRATE. None
Pre - PA Allowance None Prior-Approval Requirements Prior authorization is not required if prescribed by an oncologist and/or the member has paid pharmacy claims for an oncology medication(s) in the past
More informationPsychopharmacology & Clinical Practice: Helping or Hurting?
American Psychiatric Nurses Association VII Clinical Psychopharmacology Institute Reston, Virginia June 27, 2009 Psychopharmacology & Clinical Practice: Helping or Hurting? Ross J. Baldessarini, M.D. Professor
More informationBriefly state the reason for this evaluation: Patient s Name: Sex: Male/Female (circle one) Date of Birth: Age: Patient s Social Security #
Psychiatric Evaluation Form After Hours Psychiatry, PLLC Aaron Alaniz, M.D. 25722 Kingsland Blvd, Suite 202 Katy, TX 77494 T: 281-978-2515 F: 281-978-2895 Briefly state the reason for this evaluation:
More informationAll formulary medications available in generic form are supplied in generic form. Requests for brand name preparations must get prior authorization.
Title 19/21 GMH/SA & Non-Title 19/21 SMI Behavioral Health Drug List Updated 10/01/2018 About the Behavioral Health Drug List The Mercy Care behavioral health drug list includes all of the behavioral health
More informationPatients considering TMS Therapy
Charles Hayden MD Patients considering TMS Therapy Thank you for your interest in TMS Therapy. Please take time before you meet with Dr. Hayden to carefully fill out this form as completely as possible.
More informationPediatric Psychopharmacology: Erika Ryst, M.D. October 12, 2016
Pediatric Psychopharmacology: Erika Ryst, M.D. October 12, 2016 Good psychopharmacology depends on Proper use of safe and effective meds Treatment of other obvious factors (e.g., medical conditions, toxic
More informationNew Jersey Department of Children and Families Office of Child Health Services. Psychotropic Medication Policy
New Jersey Department of Children and Families Office of Child Health Services Psychotropic Policy January 14, 2010 (Revised May 17, 2011) Allison Blake, PhD LSW Commissioner NJ Department of Children
More information8/15/17. Managing Psychiatric Conditions in Primary Care Beyond the Basics. Speaker s Biography. Situation
Managing Psychiatric Conditions in Primary Care Beyond the Basics Source: US National Library of Medicine, Images from the History of Medicine Luis Berrios, DNP, MHA, ANP, PMHNP Internal Medicine & Primary
More informationYouth Indicator Set. Technical Specifications. July NYS Office of Mental Health
Youth Indicator Set July 2010 Technical Specifications NYS Office of Mental Health Youth Indicators Documentation 2 The PSYCKES Youth Indicators Technical Specifications Youth Psychotropic Prescribing
More informationTitle 19/21 GMH/SA & Non-Title 19/21 SMI Behavioral Health Drug List Updated 01/01/2017
Title 19/21 GMH/SA & Non-Title 19/21 SMI Behavioral Health Drug List Updated 01/01/2017 Effective April 1, 2014, Mercy Maricopa Integrated Care began operations as the Regional Behavioral Health Authority
More informationA Primer on Psychotropic Medications. Michael Flaum, MD
The Iowa Mental Health System and Employment for Individuals with Psychiatric Conditions Iowa Vocational Rehabilitation Services Conference Des Moines, IA, September 18, 2006 A Primer on Psychotropic Medications
More informationToo Many Meds? How to Prevent Polypharmacy in People with Intellectual/Developmental Disabilities
Too Many Meds? How to Prevent Polypharmacy in People with Intellectual/Developmental Disabilities One definition of polypharmacy is using more medications than is medically necessary. However, it can be
More informationMedications for Treating Mental Illnesses 3.0 Contact Hours Presented by: CEU Professor
Medications for Treating Mental Illnesses 3.0 Contact Hours Presented by: CEU Professor 7 www.ceuprofessoronline.com Copyright 8 2007 The Magellan Group, LLC All Rights Reserved. Reproduction and distribution
More informationTitle 19/21 GMH/SA & Non-Title 19/21 SMI Behavioral Health Drug List Updated 4/01/2018
Title 19/21 GMH/SA & Non-Title 19/21 SMI Behavioral Health Drug List Updated 4/01/2018 Effective April 1, 2014, Mercy Maricopa Integrated Care began operations as the Regional Behavioral Health Authority
More informationCHILD/ADOLESCENT INTAKE FORM
CHILD/ADOLESCENT INTAKE FORM Today's date: 703-437-6311 www.centerforlifestrategies.com Patient Information: Individual Name: Date of Birth: Age: (fi rst) ( la st) Gender M/F Ethnicity (optional): Name
More informationJohn E. Kraus, M.D., Ph.D.
John E. Kraus, M.D., Ph.D. Chief, Adult Psychiatry, Dorothea Dix Hospital, Raleigh, NC Assistant Professor/Associate Director of Residency Training, Dept. of Psychiatry, UNC Hospitals, Chapel Hill, NC
More informationDepression. University of Illinois at Chicago College of Nursing
Depression University of Illinois at Chicago College of Nursing 1 Learning Objectives Upon completion of this session, participants will be better able to: 1. Recognize depression, its symptoms and behaviors
More informationIR PROCEDURE REFERENCE GUIDE
IR PROCEDURE REFERENCE GUIDE Procedure Scan Involvement Preparation Length For Procedure CT CT BIOPSIES/ DRAINS Done per Radiologist in CT (Must be pre-approved by Radiologist) NPO after midnight or 6
More informationThe Basics of Psychoactive/Psychotropic Medications Tina Sanchez, RN, SMQT New Mexico Department of Health Division of Health Improvement State
The Basics of Psychoactive/Psychotropic Medications Tina Sanchez, RN, SMQT New Mexico Department of Health Division of Health Improvement State RAI/MDS Coordinator Objectives Upon completion of this training,
More informationLifePath Systems Medication and Laboratory Formulary
Building stronger communities, person by person LifePath Systems Medication and Laboratory Formulary Last update: 12/04/2018 1 Table of Contents Introduction/Contact Information 3 PAP Medications Overview
More informationOBJECTIVES PSYCHOTROPIC MEDICATIONS WHAT IS PSYCHOTROPIC MEDICATION?
PSYCHOTROPIC MEDICATIONS Sally Davies, Ph.D., HSPP Licensed Psychologist OBJECTIVES 1. Identify psychotropic medications and the typical usages 2. Identify effective methods for the practical application
More informationNational Professional Development Center on Autism Spectrum Disorders
National Professional Development Center on Autism Spectrum Disorders Parent and Child Information Questionnaire Thank you for taking time to complete this questionnaire. This information will help us
More informationOhana Community Care Services (CCS) Comprehensive Preferred Drug List (List of Covered Drugs)
2015 Ohana Community Care Services (CCS) Comprehensive referred Drug List (List of Covered Drugs) Ohana Health lan 00 lease read: This document contains information about the drugs we cover in this plan.
More informationPsychiatric Medication Guide
Psychiatric Medication Guide F O R : N E O N P R I M A R Y H E A L T H C A R E P R O V I D E R S B Y : M I C H E L L E R O M E R O, D O M A Y, 2 0 1 3 Anti-depressants TCA s & MAOI s (Tricyclic Antidepressants
More informationTitle 19/21 GMH/SA & Non-Title 19/21 SMI Behavioral Health Drug List Updated 05/01/2015
Title 19/21 GMH/SA & Non-Title 19/21 SMI Behavioral Health Drug List Updated 05/01/2015 Effective April 1, 2014, Mercy Maricopa Integrated Care began operations as the Regional Behavioral Health Authority
More informationPatient Registration Form. Patient Name: Social Security #: Billing Address: City: State: Zip Code: Home Address. Home Phone#: Cell #: Work #:
1 Patient Registration Form Date: Patient Name: Social Security #: Date of Birth: Age: Billing Address: City: State: Zip Code: Home Address City: State: Zip Code: Home Phone#: Cell #: Work #: Email Address:
More informationIowa Medicaid Mental Health Advisory Group Meeting February 13, Tentative Agenda
CHESTER J. CULVER, GOVERNOR PATTY JUDGE, LT. GOVERNOR DEPARTMENT OF HUMAN SERVICES EUGENE I. GESSOW, DIRECTOR Iowa Medicaid Mental Health Advisory Group Meeting February 13, 2009 Location: Iowa Medicaid
More informationPharmacotherapy of Anxiety Disorders (GAD, Panic, & SAD) Declaration of Interests
Pharmacotherapy of Anxiety Disorders (GAD, Panic, & SAD) University of Texas Health Science Center San Antonio Pharmacotherapy Education and Research Center (PERC) 7703 Floyd Curl Drive - MSC 6220 San
More information